text
"['\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2022년 09월 30일\n)\n(단위 : 백만원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n(주)티움바이오\n상장\n2019.04.30\n투자\n3,000\n125,000\n0.53\n2,413\n-\n-\n-806\n125,000\n0.53\n1,607\n113,722\n-32,253\n일성신약(주)\n상장\n2006.06.05\n투자\n930\n1,000\n0.04\n74\n-\n-105\n31\n-\n-\n-\n371,383\n-1,368\n한국제약협동조합\n비상장\n1978.04.04\n공동출자\n162\n663\n6.26\n162\n-\n-\n-\n663\n6.26\n162\n12,147\xa0\n-3,227\n씨씨알(주)\n비상장\n2005.01.02\n투자\n74\n13,489\n0.32\n-\n-\n-\n-\n13,489\n0.32\n-\n8,674\n75\n(주)퓨어스피어\n비상장\n2016.11.03\n투자\n300\n3,000\n6.52\n218\n-\n-\n-\n3,000\n6.52\n218\n11,686\n1227\n프리미어 글로벌 이노베이션1호 투자조합\n비상장\n2017.06.15\n투자\n560\n-\n4.00\n2,663\n-\n-319\n-\n-\n4.00\n2,344\n44,895\n\xa03,735\n라이프코어-이앤 신기술 사업투자조합 1호\n비상장\n2017.08.10\n투자\n500\n-\n12.20\n500\n-\n-\n-\n-\n12.20\n500\n\xa02,044\n\xa0 -106\n수성코스닥벤처 멀티에셋공모주 사모투자신탁 2호\n비상장\n2018.06.07\n투자\n1,000\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1,050\n13,828\n수성코스닥벤처 M6 전문투자형 사모투자신탁\n비상장\n2020.10.16\n투자\n2,000\n-\n-\n2,379\n-\n-\n-\n-\n-\n2,379\n\xa026,274\n-1,723\n(주)클리노믹스\n상장\n2018.07.20\n투자\n1,000\n138,928\n1.04\n1,799\n-\n-\n-903\n138,928\n1.04\n896\n102,587\n\xa015,853\n시너지 바이오 헬스케어 벤처펀드\n비상장\n2019.05.16\n투자\n601\n-\n-\n1,768\n-\n-\n-\n-\n-\n1,768\n24,731\n\xa01,061\n보고신기술사업금융전문투자형 사모투자신탁 제2호\n비상장\n2019.06.04\n투자\n1,000\n-\n-\n740\n-\n-\n-\n-\n-\n740\n\xa0 10,337\n-3,354\nDS Benefit,XV 전문투자형 사모투자신탁\n비상장\n2020.05.29\n투자\n300\n-\n-\n300\n-\n-\n-\n-\n-\n300\n\xa04,509\n1\n주식회사 엘베이스\n비상장\n2020.12.28\n투자\n2,000\n93,053\n5.97\n2,000\n-\n-\n-\n93,053\n5.97\n2,000\n\xa05,372\n-2,182\n프리미어 글로벌 이노베이션 2호 투자조합\n비상장\n2020.11.03\n투자\n250\n-\n-\n2,408\n-\n885\n-\n-\n-\n3,293\n\xa058,605\n-483\n엠투엔 제14회차 사모 전환사채\n비상장\n2021.06.28\n투자\n1,017\n-\n-\n1,017\n-\n-\n-\n-\n-\n1,017\n190,098\n\xa0-58,552\n신보2021제14차유동화전문회사 제1-3회 무보증후순위공모사채\n비상장\n2021.08.27\n투자\n270\n-\n-\n270\n-\n-\n-\n-\n-\n270\n623,463\n\xa0186\nNH 앱솔루트 코스닥벤처 메자닌 1호\n비상장\n2021.09.23\n투자\n2,000\n-\n-\n1,951\n-\n-\n-\n-\n-\n1,951\n\xa051,782\n\xa0-124\n더블유피 기술혁신 스타트업 2호조합\n비상장\n2021.11.19\n투자\n200\n-\n-\n200\n-\n-\n-\n-\n-\n200\n\xa0764\n\xa0-3\n디지털 이노베이션 벤처투자조합\n비상장\n2021.12.16\n투자\n3,000\n-\n29.24\n3,000\n-\n-\n-\n-\n29.24\n3,000\n\xa010,254\n\xa0 -6\n수성프로젝트 T1 일반 사모투자신탁\n비상장\n2022.01.26\n투자\n2,000\n-\n-\n-\n-\n2,000\n-\n-\n-\n2,000\n-\n-\nList Biotherapeutics, Inc.\n비상장\n2022.01.14\n투자\n3,570\n-\n-\n-\n-\n3,570\n-\n-\n-\n3,570\n-\n-\n글라세움 우선주\n비상장\n2022.04.01\n투자\n3,000\n-\n-\n-\n-\n3,000\n-\n-\n-\n3,000\n-\n-\n대원메디테크(주)\n비상장\n2011.04.12\n경영참여\n2,300\n2,799,999\n64.42\n-\n-\n-\n-\n2,799,999\n64.42\n-\n2,641\n-1,032\n(주)다나젠\n비상장\n2015.12.11\n경영참여\n40\n679,184\n28.60\n1,040\n-24,000\n-37\n-\n655,184\n27.58\n1,003\n15,622\n2,055\nDAEWON PHARMACEUTICAL(Vietnam) Co., Ltd.\n비상장\n2017.07.31\n경영참여\n430\n-\n100.00\n836\n-\n-\n-\n-\n100.00\n836\n477\n-311\n극동에치팜 주식회사\n비상장\n2021.05.26\n경영참여\n14,114\n60,553\n83.53\n14,602\n-\n-\n-\n60,553\n83.53\n14,602\n28,785\n95\n합 계\n3,914,869\n-\n40,340\n-24,000\n8,994\n-1,678\n3,889,869\n-\n47,656\n-\n-\n주) 최근 사업연도 재무현황은 21년(말) 기준 금액입니다. 단, \xa0수성코스닥벤처 멀티에셋공모주 사모투자신탁 2호의 경우 21년 종료로 20년말 재무현황 기재하였으며, 22년도 출시 상품의 경우 21년도 재무 현황 기재를 생략 하였습니다.\n']"
